Valneva’s (VALN) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright restated their buy rating on shares of Valneva (NASDAQ:VALN) in a report issued on Monday,Benzinga reports. HC Wainwright currently has a $17.00 price objective on the stock.

Separately, Guggenheim decreased their price target on shares of Valneva from $17.00 to $15.00 and set a “buy” rating for the company in a research note on Monday, March 24th.

Valneva Stock Up 2.4 %

Shares of NASDAQ VALN opened at $6.92 on Monday. Valneva has a 52-week low of $3.62 and a 52-week high of $9.50. The stock has a market cap of $562.33 million, a P/E ratio of -53.23 and a beta of 1.93. The company has a debt-to-equity ratio of 0.70, a quick ratio of 2.25 and a current ratio of 2.78. The firm has a 50 day moving average price of $6.76 and a 200 day moving average price of $5.60.

Valneva (NASDAQ:VALN) last issued its quarterly earnings data on Thursday, March 20th. The company reported ($0.54) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.22) by ($0.32). Valneva had a negative net margin of 4.35% and a negative return on equity of 3.93%. The business had revenue of $56.48 million during the quarter, compared to analyst estimates of $55.64 million. Analysts expect that Valneva will post 0.13 EPS for the current year.

Hedge Funds Weigh In On Valneva

A hedge fund recently bought a new stake in Valneva stock. ABC Arbitrage SA bought a new position in shares of Valneva SE (NASDAQ:VALN) during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 19,244 shares of the company’s stock, valued at approximately $84,000. 11.39% of the stock is owned by institutional investors and hedge funds.

About Valneva

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.